Bioinformatics Institute of India: Pharma Department

Indian Bio-pharma industry accounts for 65% of the biotech sector

Indian bio-Pharma industry is valued at Rs. 7,883 crore and is registering 14.25 per cent annual growth. The sector accounts for 65 per cent of the total biotech sector which is valued at Rs. 12.137 crore, according to the Association of Biotechnology Led Entrepreneurs and Biospectrum survey.

The bio Pharma sector continues to grow, stated Kiran Mazumdar-Shaw, CMD, Biocon.

Emerging markets is certainly a strong focus now with many global biopharma companies. Emerging markets are seen to be the highest growth opportunities and this is really about addressing stagnating top line growth amongst companies. Late stage asset acquisition is another very interesting trend. This is, again, to address the declining pipelines and filling them up with late stage assets that can accelerate time to market, stated Shaw at the JP Morgan Healthcare Conference held at San Francisco early this month.

One of the biggest risk that the industry is addressing is about the increasing risks and costs associated with drug development. And here, industry is beginning to experiment with new risk sharing models. Co-development is an interesting strategy. Outsourcing R&D services to reduce cost is another way of looking at cost mitigation in drug innovation, she added.

India has a handful of dedicated bio-Pharma companies which manufacture using fermentation process known as MAbs  which primarily include cancer drugs, insulin, growth hormones, and cell culture to produce vaccines, While Biocon is the largest in the space with range of bio-pharma products gearing a revenue of Rs. 100 cr to its total turnover of Rs. 1,739 cr. The other companies are Panacea Biotec, Novo Nordisk, Shanta Biotech, Jubilant, Bharat Biotech India Immunologicals, Bharat Serums, Themis Medicare, Concord Biotech, Intas Biopharma, GSK, Wockhadt Serum International, Dr. Reddy’s Lab and Aventis.